secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axe Compute Inc. (AGPU)
CIK:        0001446159
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001171843-25-005403
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Predictive Oncology Q2 loss $0.22/share; revenue $2.7K; ChemoFx U.S./EU launch expected Q4 2025
--------------------------------------------------------------------------------

- Loss from continuing ops ~$2.0M; diluted EPS -$0.22 vs -$0.53 YoY.
- Revenue $2,682, down 96% from $67,255 due to lower 3D model sales.
- Cash $506K; stockholders' deficit $1.65M vs $202K at Dec 31, 2024.
- Signed $10M standby equity purchase agreement with Yorkville Advisors.
- Advanced ChemoFx market expansion; developed 3D liver models for Labcorp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446159/000117184325005403/0001171843-25-005403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446159/000117184325005403/f8k_081325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer